PVH
6.10.2020 18:02:13 CEST | Business Wire | Press release
PVH Europe, the global headquarters of Tommy Hilfiger and the European offices of Calvin Klein, both owned by PVH Corp. [NYSE: PVH], announces the installation of what is believed to be the world’s most powerful* currently operational solar roof at its state-of-the-art Warehouse and Logistics Center in Venlo, the Netherlands. Generated by more than 48,000 solar panels, the solar roof covers the Center’s electricity footprint, as well as indirectly providing 100% of all energy for PVH Europe’s warehouses, offices and stores in the Netherlands via the Dutch public power network. PVH Europe’s energy partner, Eneco, has certified that all energy needed to power these buildings is generated by the new rooftop installation. The Venlo Warehouse and Logistics Center is owned by Heylen Warehouses, a Belgian logistics real estate company, in a joint venture with AG Real Estate, and retained IZEN as the technical installation partner for the roof.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201006005513/en/
This milestone marks another step in PVH’s journey to procure 100% of its electricity from renewable sources for its offices, warehouses and stores, and to drive a 30% reduction in supply chain carbon emissions by 2030. This work is linked to PVH’s science-based emissions target aligned with the most ambitious level of decarbonization as set out by the Paris Agreement. It is also one of the priorities outlined in the company’s Forward Fashion corporate responsibility strategy, which aims to reduce negative impacts to zero, increase positive impacts to 100% and improve the over 1 million lives across the company’s value chain.
Key Facts:
- The Venlo warehouse is PVH Europe’s main distribution center covering 110,000m2 .
- Awarded a BREEAM (Building Research Establishment Environmental Assessment Method) sustainability rating of “Very Good”.
- The world’s most powerful solar roof, with a capacity to generate 18 MWp (megawatt peak).
- Facilitated by over 48,000 high performance solar panels.
- Fully powers all PVH Europe owned stores, warehouses and offices in the Netherlands.
“This is an incredible milestone for our Warehouse and Logistics Center in Venlo and for PVH Europe’s sustainability journey,” said Martijn Hagman, CEO ,Tommy Hilfiger Global and PVH Europe. “We have participated in the installation of what we believe is now the world’s most powerful, fully operational solar roof – a huge stride in our commitment to be powered by 100% renewable electricity by 2030 and reduce supply chain emissions by 30% by 2030. This would not have been possible without a best-in-class team of such talented, passionate, and devoted PVH associates.”
At present, up to 600,000 pieces of TOMMY HILFIGER and CALVIN KLEIN product are distributed daily from the PVH Europe Warehouse and Logistics Center in Venlo to points of sale, including owned and operated stores in Europe, the Middle East and Africa, and direct to customers. The warehouse’s Very Good rating by BREEAM incorporates exemplary standards for energy, water, transport, materials, waste, pollution, ecology, health and well-being. This is reflected through energy efficient lighting in 100% of the space, the use of 100% FSC (Forest Stewardship Council) certified packaging and 100% recycling of all cardboard, plastics and printed material.
PVH is a member of RE100, the corporate renewable electricity initiative led by the Climate Group, and has committed to RE100 to procure 100% of its electricity from renewable sources by 2030.
Sam Kimmins, Head of RE100 at the Climate Group said: “Congratulations to PVH on the finalization of the Venlo solar rooftop. This is another exciting step in their global work and partnership towards their 2025 RE100 target. It raises the bar once more for on-site renewables.”
“ We believe that logistic buildings will be the next generation of solar power plants,” said Philippe Deschilder, CEO of Heylen Warehouses. “The partnership with PVH Europe for the solar roof project supports our ambition to invest in renewable energy, creating added value for our customers by enabling them to reduce their carbon footprint.”
About PVH Corp.
PVH is one of the most admired fashion and lifestyle companies in the world. We power brands that drive fashion forward – for good. Our brand portfolio includes the iconic CALVIN KLEIN , TOMMY HILFIGER , Van Heusen , IZOD , ARROW, Warner’s , Olga and Geoffrey Beene brands, as well as the digital-centric True&Co. intimates brand. We market a variety of goods under these and other nationally and internationally known owned and licensed brands. PVH has over 40,000 associates operating in over 40 countries and $9.9 billion in annual revenues. That's the Power of Us. That’s the Power of PVH.
Follow us on Facebook , Instagram , Twitter and LinkedIn .
About RE100
RE100 is a global initiative bringing together the world’s most influential businesses committed to 100% renewable power. Led by the Climate Group in partnership with CDP , the group has a total revenue of over US$5.4 trillion and operates in a diverse range of sectors. Together, they send a powerful signal to policymakers and investors to accelerate the transition to a clean economy. #RE100
*PVH defines the “world’s most powerful solar roof” as the most powerful solar roof that is currently operational and installed on one singular structure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005513/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
